Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
FDA approves belzutifan for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Belzutifan for advanced kidney cancer: long-term follow-up
Studies looking at the genes of people with kidney cancer have shown [...]
New treatment, zanzalintinib, for advanced kidney cancer
A recent clinical trial looked at a new anti-cancer medication [...]
Treatment of translocation kidney cancer
Translocation kidney cancer is a rare type of kidney cancer [...]
Real world treatment of advanced kidney cancer
Nearly 30% of new kidney cancer cases are diagnosed at [...]
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
